Jason Ryan
CIK 1585017 · Executive Chairman · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.35M
Companies
7
Total Filings
67
Lifetime Open-Market Net
-$18.54M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WGS | Director | 118,764 | $61.88 | $7.35M | $0 | 1 | 2026-06-23 |
| WGSWW | Director | 135,473 | $0.00 | $27 | -$8.15M | 11 | 2025-08-27 |
| Singular Genomics Systems, Inc. (OMIC) Delisted | Director | — | $20.01 | — | $0 | 3 | 2024-05-31 |
| SomaLogic, Inc. (SLGCW) Delisted | Director | — | $0.09 | — | $0 | 1 | 2023-06-12 |
| GeneDx Holdings Corp. (SMFRW) Delisted | Executive Chairman | 263,358 | $0.02 | $6.3K | -$20.4K | 6 | 2023-01-04 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | See Remarks | — | $11.19 | — | $0 | 2 | 2020-02-12 |
| Foundation Medicine, Inc. (FMI) Delisted | Chief Financial Officer | 49,170 | — | — | -$10.37M | 38 | 2018-07-05 |
Recent Filings · Page 2 of 7
67 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-12 | WGSWW | Gift (G) | −73,614 | $0 | EDGAR |
| 2024-01-09 | — | Disp (D) | — | $0 | |
| 2024-01-03 | WGSWW | Exer (M) | +67,780 | $0 | EDGAR |
| 2023-11-20 | WGSWW | Buy (P) | +114,742 | $161.4K | EDGAR |
| 2023-10-18 | WGSWW | Sell (S) | −42 | -$134 | EDGAR |
| 2023-10-17 | WGSWW | Exer (M) | +129 | $0 | EDGAR |
| 2023-06-12 | SomaLogic, Inc. (SLGCW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-26 | Singular Genomics Systems, Inc. (OMIC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-04-27 | WGSWW | Grant (A) | — | $0 | EDGAR |
| 2023-01-04 | GeneDx Holdings Corp. (SMFRW) Delisted | Mixed | +173,793 | -$19.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.